A citation-based method for searching scientific literature

K L Burns, K Ueki, S L Jhung, J Koh, D N Louis. J Neuropathol Exp Neurol 1998
Times Cited: 102







List of co-cited articles
749 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
K Ueki, Y Ono, J W Henson, J T Efird, A von Deimling, D N Louis. Cancer Res 1996
385
50

Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas.
W Biernat, Y Tohma, Y Yonekawa, P Kleihues, H Ohgaki. Acta Neuropathol 1997
134
28





The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53.
J Pomerantz, N Schreiber-Agus, N J Liégeois, A Silverman, L Alland, L Chin, J Potes, K Chen, I Orlow, H W Lee,[...]. Cell 1998
18


CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.
E E Schmidt, K Ichimura, G Reifenberger, V P Collins. Cancer Res 1994
448
18

A cell cycle regulator potentially involved in genesis of many tumor types.
A Kamb, N A Gruis, J Weaver-Feldhaus, Q Liu, K Harshman, S V Tavtigian, E Stockert, R S Day, B E Johnson, M H Skolnick. Science 1994
17

Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices.
Y Ono, T Tamiya, T Ichikawa, K Kunishio, K Matsumoto, T Furuta, T Ohmoto, K Ueki, D N Louis. J Neuropathol Exp Neurol 1996
83
19

Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
J G Herman, J R Graff, S Myöhänen, B D Nelkin, S B Baylin. Proc Natl Acad Sci U S A 1996
16

Cancer cell cycles.
C J Sherr. Science 1996
16

PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas.
Y Tohma, C Gratas, W Biernat, A Peraud, M Fukuda, Y Yonekawa, P Kleihues, H Ohgaki. J Neuropathol Exp Neurol 1998
191
16

Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations.
G Reifenberger, L Liu, K Ichimura, E E Schmidt, V P Collins. Cancer Res 1993
548
15

The retinoblastoma gene is involved in malignant progression of astrocytomas.
J W Henson, B L Schnitker, K M Correa, A von Deimling, F Fassbender, H J Xu, W F Benedict, D W Yandell, D N Louis. Ann Neurol 1994
195
15


Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme.
Y Hayashi, K Ueki, A Waha, O D Wiestler, D N Louis, A von Deimling. Brain Pathol 1997
112
15

5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers.
A Merlo, J G Herman, L Mao, D J Lee, E Gabrielson, P C Burger, S B Baylin, D Sidransky. Nat Med 1995
14

Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies.
K Watanabe, K Sato, W Biernat, O Tachibana, K von Ammon, N Ogata, Y Yonekawa, P Kleihues, H Ohgaki. Clin Cancer Res 1997
199
14


Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes.
E W Newcomb, H Cohen, S R Lee, S K Bhalla, J Bloom, R L Hayes, D C Miller. Brain Pathol 1998
161
13

Deletion of p16 and p15 genes in brain tumors.
J Jen, J W Harper, S H Bigner, D D Bigner, N Papadopoulos, S Markowitz, J K Willson, K W Kinzler, B Vogelstein. Cancer Res 1994
476
13

Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation.
J F Costello, M S Berger, H S Huang, W K Cavenee. Cancer Res 1996
222
13


MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.
T Moulton, G Samara, W Y Chung, L Yuan, R Desai, M Sisti, J Bruce, B Tycko. Am J Pathol 1995
85
14

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.
P A Steck, M A Pershouse, S A Jasser, W K Yung, H Lin, A H Ligon, L A Langford, M L Baumgard, T Hattier, T Davis,[...]. Nat Genet 1997
12

Subsets of glioblastoma multiforme defined by molecular genetic analysis.
A von Deimling, K von Ammon, D Schoenfeld, O D Wiestler, B R Seizinger, D N Louis. Brain Pathol 1993
309
12

Amplification and overexpression of MDM2 in primary (de novo) glioblastomas.
W Biernat, P Kleihues, Y Yonekawa, H Ohgaki. J Neuropathol Exp Neurol 1997
130
12

MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p.
K Ueki, M P Rubio, V Ramesh, K M Correa, J L Rutter, A von Deimling, A J Buckler, J F Gusella, D N Louis. Hum Mol Genet 1994
121
11

Somatic mutations of PTEN in glioblastoma multiforme.
S I Wang, J Puc, J Li, J N Bruce, P Cairns, D Sidransky, R Parsons. Cancer Res 1997
446
11


PTEN mutations in gliomas and glioneuronal tumors.
E M Duerr, B Rollbrocker, Y Hayashi, N Peters, B Meyer-Puttlitz, D N Louis, J Schramm, O D Wiestler, R Parsons, C Eng,[...]. Oncogene 1998
286
10

Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers.
T Nobori, K Miura, D J Wu, A Lois, K Takabayashi, D A Carson. Nature 1994
10

Role of the INK4a locus in tumor suppression and cell mortality.
M Serrano, H Lee, L Chin, C Cordon-Cardo, D Beach, R A DePinho. Cell 1996
10


CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines.
J He, J R Allen, V P Collins, M J Allalunis-Turner, R Godbout, R S Day, C D James. Cancer Res 1994
259
10

Germline p16 mutations in familial melanoma.
C J Hussussian, J P Struewing, A M Goldstein, P A Higgins, D S Ally, M D Sheahan, W H Clark, M A Tucker, N C Dracopoli. Nat Genet 1994
9

Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression.
J Reifenberger, G U Ring, U Gies, L Cobbers, J Oberstrass, H X An, D Niederacher, W Wechsler, G Reifenberger. J Neuropathol Exp Neurol 1996
151
9

Loss of P16INK4 expression is frequent in high grade gliomas.
R Nishikawa, F B Furnari, H Lin, W Arap, M S Berger, W K Cavenee, H J Su Huang. Cancer Res 1995
141
9

Structural alterations of the epidermal growth factor receptor gene in human gliomas.
A J Wong, J M Ruppert, S H Bigner, C H Grzeschik, P A Humphrey, D S Bigner, B Vogelstein. Proc Natl Acad Sci U S A 1992
699
9

The p53 gene and protein in human brain tumors.
D N Louis. J Neuropathol Exp Neurol 1994
301
9

Genetic alterations associated with the evolution and progression of astrocytic brain tumours.
H Ohgaki, B Schäuble, A zur Hausen, K von Ammon, P Kleihues. Virchows Arch 1995
135
9

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.
J Li, C Yen, D Liaw, K Podsypanina, S Bose, S I Wang, J Puc, C Miliaresis, L Rodgers, R McCombie,[...]. Science 1997
9


Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas.
J Fueyo, C Gomez-Manzano, J M Bruner, Y Saito, B Zhang, W Zhang, V A Levin, W K Yung, A P Kyritsis. Oncogene 1996
76
11

The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.
F J Stott, S Bates, M C James, B B McConnell, M Starborg, S Brookes, I Palmero, K Ryan, E Hara, K H Vousden,[...]. EMBO J 1998
945
9

A novel p16INK4A transcript.
L Mao, A Merlo, G Bedi, G I Shapiro, C D Edwards, B J Rollins, D Sidransky. Cancer Res 1995
332
8


Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
J G Cairncross, K Ueki, M C Zlatescu, D K Lisle, D M Finkelstein, R R Hammond, J S Silver, P C Stark, D R Macdonald, Y Ino,[...]. J Natl Cancer Inst 1998
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.